HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Clinical trials for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Milder cancer treatment after robotic surgery aims to cut side effects for HPV-positive throat cancer patients
Disease control OngoingThis study looks at whether a lower-dose version of standard chemo-radiation can work just as well for people with HPV-positive throat cancer after robotic surgery, while causing fewer side effects. About 40 patients who have had or will have surgery to remove their cancer will r…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Cedars-Sinai Medical Center • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
Throat cancer breakthrough: less treatment, same results?
Disease control OngoingThis study looks at whether people with HPV-positive throat cancer can safely receive less intense treatment after surgery. Standard treatment often includes chemotherapy and radiation, which can cause long-term side effects. The goal is to see if scaling back or stopping some tr…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated May 26, 2026 07:53 UTC
-
Custom immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a personalized cell therapy called T-Plex for people with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize and attack cancer cells. The main goal is to check s…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: TScan Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
New combo therapy aims to boost immune attack against HPV-driven head and neck cancer
Disease control OngoingThis phase 3 study tests whether adding an experimental immunotherapy (PDS0101) to standard pembrolizumab helps people with advanced HPV16-positive head and neck cancer live longer or delay cancer growth. About 252 participants will receive either the combination or pembrolizumab…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: PDS Biotechnology Corp. • Aim: Disease control
Last updated May 26, 2026 07:25 UTC
-
Experimental vaccine combo aims to shrink throat tumors and cut radiation dose
Disease control OngoingThis study tests whether adding experimental drugs HB-201 and HB-202 to standard chemotherapy can shrink HPV16-positive throat tumors more effectively. The goal is to reduce the amount of radiation and chemotherapy needed afterward, potentially lowering side effects. About 35 adu…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 26, 2026 07:24 UTC
-
Blood test may sniff out hidden throat cancer
Diagnosis OngoingThis study is testing whether a blood test (NavDx®) can find early signs of HPV-related oropharyngeal cancer by looking for tiny bits of HPV DNA in the bloodstream. Researchers are enrolling 9 people aged 45 and older with multiple sexual partners to see how many cases the test c…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated May 19, 2026 12:00 UTC
-
Could a vaccine stop oral HPV in men with HIV?
Prevention OngoingThis study tests the 9-valent HPV vaccine in 700 men living with HIV to see if it can prevent long-lasting oral HPV infections that can lead to cancer. Participants receive the vaccine or a placebo and are followed for up to four years. The goal is to stop HPV types linked to thr…
Matched conditions: HPV POSITIVE OROPHARYNGEAL SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Weill Medical College of Cornell University • Aim: Prevention
Last updated May 26, 2026 07:51 UTC